Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of Broluciumab

NCT05037396 · clinicaltrials.gov ↗

COMPLETED

Status

9457

Enrollment

INDUSTRY

Sponsor class

Conditions

Age-related Macular Degeneration (AMD)

Interventions

DRUG: Brolucizumab

Sponsor

Novartis Pharmaceuticals